The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $91.62

Today's change+4.11 +4.70%
Updated February 27 4:00 PM EST. Delayed by at least 15 minutes.
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $91.62

Today's change+4.11 +4.70%
Updated February 27 4:00 PM EST. Delayed by at least 15 minutes.

Biomarin Pharmaceutical Inc crosses above 200-day moving average

Biomarin Pharmaceutical Inc closed up sharply Monday, rallying (U.S.)$4.11 or 4.70% to (U.S.)$91.62 and crossing above its 200-day moving average. Over the last five days, shares have gained 1.95% and 10.60% year to date. Shares have underperformed the S&P 500 by 7.32% during the last year.

Key company metrics

  • Open(U.S.) $87.26
  • Previous close(U.S.) $87.51
  • High(U.S.) $91.74
  • Low(U.S.) $87.26
  • Bid / Ask(U.S.) $85.08 / (U.S.) $92.54
  • YTD % change+10.60%
  • Volume1,340,772
  • Average volume (10-day)1,179,603
  • Average volume (1-month)1,062,384
  • Average volume (3-month)1,224,874
  • 52-week range(U.S.) $73.45 to (U.S.) $102.49
  • Beta1.57
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$3.72
Updated February 27 4:00 PM EST. Delayed by at least 15 minutes.

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2016Q3/2016Q2/2016Q1/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue300280300237
Total other revenue--------
Total revenue300280300237
Gross profit236229249194
Total cost of revenue64515243
Total operating expense390340873318
Selling / general / administrative14312011098
Research & development175161167159
Depreciation / amortization--888
Interest expense (income), net operating--------
Unusual expense (income)005990
Other operating expenses, total72-623
Operating income-90-60-573-81
Interest income (expense), net non-operating-10-10-10-10
Gain (loss) on sale of assets--------
Other--------
Income before tax-92-67-583-89
Income after tax-91-43-424-85
Income tax, total-1-24-159-4
Net income-91-43-424-85
Total adjustments to net income--------
Net income before extra. items-91-43-424-85
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-91-43-424-85
Inc. avail. to common incl. extra. items-91-43-424-85
Diluted net income-91-43-424-85
Dilution adjustment--------
Diluted weighted average shares172168163162
Diluted EPS excluding extraordinary itemsvalue per share-0.53-0.26-2.61-0.53
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share-0.53-0.26-0.21-0.53